🔎 Trials Near Me

Почетна › Hronična mijelomonocitna leukemija › Вашингтон › Seattle

Kliničke studije za Hronična mijelomonocitna leukemija u gradu Seattle, WA

10 studija za Hronična mijelomonocitna leukemija traži učesnike na lokacijama u gradu Seattle i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.

Zvanični tekst studije (na engleskom)

Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Тражи се учесникФаза 2/3
  • Seattle Cancer Care Alliance, Seattle
Узраст 18 и старији · Оба пола · Ажурирано 6. 10. 2026. · NCT04256317

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Тражи се учесникФаза 1
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Узраст 18 и старији · Оба пола · Ажурирано 17. 9. 2026. · NCT04375631

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Тражи се учесникФаза 2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Узраст 18 и старији · Оба пола · Ажурирано 20. 7. 2026. · NCT07046078

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

Тражи се учесникФаза 1/2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Узраст од 18 до 75 · Оба пола · Ажурирано 22. 6. 2026. · NCT03670966

211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia

Тражи се учесникФаза 1/2
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Узраст од 18 до 75 · Оба пола · Ажурирано 22. 6. 2026. · NCT03128034

Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies

Тражи се учесникФаза 2Здраве особе су добродошле
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
6 Months · Оба пола · Ажурирано 29. 5. 2026. · NCT04195633

HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Тражи се учесникФаза 1
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
До 80 година · Оба пола · Ажурирано 18. 5. 2026. · NCT03326921

Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse

Тражи се учесникФаза 1/2Здраве особе су добродошле
  • Fred Hutch/University of Washington Cancer Consortium, Seattle
Узраст 18 и старији · Оба пола · Ажурирано 15. 5. 2026. · NCT06928662

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

Тражи се учесникФаза 2
  • Fred Hutchinson Cancer Center, Seattle
Узраст од 18 до 66 · Оба пола · Ажурирано 17. 3. 2026. · NCT06859424

Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT)

Тражи се учесникФаза 1
  • Fred Hutchinson Cancer Center, Seattle
Узраст 18 и старији · Оба пола · Ажурирано 15. 4. 2025. · NCT06462365

Studije za Hronična mijelomonocitna leukemija u drugim gradovima

Ostale studije u gradu Seattle

Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.